Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- dorzolamide ophthalmic
- Zonisade (zonisamide)
Interactions between your drugs
dorzolamide ophthalmic zonisamide
Applies to: dorzolamide ophthalmic, Zonisade (zonisamide)
GENERALLY AVOID: Following ophthalmic administration, brinzolamide and dorzolamide are systemically absorbed and may have additive pharmacologic effects with other, systemically administered carbonic anhydrase inhibitors. Specific data are not available regarding coadministration with topiramate or zonisamide, which are anticonvulsants with some carbonic anhydrase inhibiting activity. Theoretically, adverse effects such as drowsiness, paresthesia, tinnitus, electrolyte imbalance, metabolic acidosis, and gastrointestinal disturbances may be increased. Carbonic anhydrase inhibition can also promote kidney stone formation by reducing urinary citrate excretion and increasing urinary pH, and cause oligohidrosis or hyperthermia by altering electrolyte and fluid balance. Oligohidrosis and hyperthermia are sometimes associated with serious sequelae but may be preventable by prompt recognition of symptoms and appropriate treatment.
MANAGEMENT: The concomitant use of ocular and systemic carbonic anhydrase inhibitors is not recommended. Patients treated with topiramate or zonisamide should be advised to increase fluid intake to enhance urinary output, which lowers the concentration of substances involved in stone formation. Patients should be monitored closely for evidence of decreased sweating and increased body temperature, especially in warm or hot weather. Proper hydration before and during vigorous activities or exposure to warm temperatures is recommended. Patients should contact their doctor immediately if they develop signs or symptoms of kidney stones such as sudden back pain, abdominal pain, blood in the urine and/or painful urination, or if they experience a rise in body temperature or decreased sweating.
References (4)
- (2001) "Product Information. Topamax (topiramate)." Ortho McNeil Pharmaceutical
- (2001) "Product Information. Azopt (brinzolamide ophthalmic)." Alcon Laboratories Inc
- (2001) "Product Information. Trusopt (dorzolamide ophthalmic)." Merck & Co., Inc
- (2001) "Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals
Drug and food interactions
zonisamide food
Applies to: Zonisade (zonisamide)
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (4)
- Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
- (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
- (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Xalatan
Xalatan (latanoprost) is used to treat certain types of glaucoma. Includes Xalatan side effects ...
Lumigan
Lumigan is used to treat open angle glaucoma. Learn about side effects, interactions and indications.
Botox
Botox is used to treat chronic migraines, excessive sweating, bladder conditions, eye muscle ...
Cosopt
Cosopt reduces the amount of fluid in the eye and is used to treat glaucoma. Learn about side ...
Combigan
Combigan (brimonidine and timolol) is used to treat glaucoma or ocular hypertension. Includes ...
Alphagan P
Alphagan P is used to treat glaucoma or ocular hypertension (high pressure inside the eye). Learn ...
Vyzulta
Vyzulta is used for glaucoma, open angle, glaucoma/intraocular hypertension
Rhopressa
Rhopressa is used for glaucoma, open angle, intraocular hypertension
Simbrinza
Simbrinza (brimonidine and brinzolamide) is used to treat open-angle glaucoma or ocular ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.